Future Live Meetings
|
Current Online Activities
The effects of both the breast malignancy and breast cancer therapy on the biology of the bone
Gregory R. Mundy, MD
Session 1 from the ancillary event held at the 2008 Breast Cancer Symposium entitled A New Targeted Strategy for Treating Bone Metastases in Breast Cancer Patients: Inhibiting RANK Ligand
Date of release: October 13, 2008
Date expires: October 13, 2009
Duration: 13:09
Click Here For More Information
Maintaining bone integrity of breast cancer patients using bisphosphonates
Allan Lipton, MD
Session 2 from the ancillary event held at the 2008 Breast Cancer Symposium entitled A New Targeted Strategy for Treating Bone Metastases in Breast Cancer Patients: Inhibiting RANK Ligand
Date of release: October 13, 2008
Date expires: October 13, 2009
Duration: 16:07
Click Here For More Information
Case Study: 64 y/o female with ER+PR+HER2- breast cancer and bone metastases
Allan Lipton, MD
Session 3 from the ancillary event held at the 2008 Breast Cancer Symposium entitled A New Targeted Strategy for Treating Bone Metastases in Breast Cancer Patients: Inhibiting RANK Ligand
Date of release: October 13, 2008
Date expires: October 13, 2009
Duration: 02:33
Click Here For More Information
Three Case Studies on the treatment of bone metastases in breast cancer patients
Catherine Van Poznak, MD
Session 4 from the ancillary event held at the 2008 Breast Cancer Symposium entitled A New Targeted Strategy for Treating Bone Metastases in Breast Cancer Patients: Inhibiting RANK Ligand
Date of release: October 13, 2008
Date expires: October 13, 2009
Duration: 11:02
Click Here For More Information
Case Study: 75 y/o Post-menopausal woman with osteoporosis who refuses to take bisphosphonates for fear of ONJ
Theresa A. Guise, MD
Session 5 from the ancillary event held at the 2008 Breast Cancer Symposium entitled A New Targeted Strategy for Treating Bone Metastases in Breast Cancer Patients: Inhibiting RANK Ligand
Date of release: October 13, 2008
Date expires: October 13, 2009
Duration: 11:42
Click Here For More Information
Can we improve the bone health of breast cancer patients by targeting the biology of the bone?
Theresa A. Guise, MD
Session 6 from the ancillary event held at the 2008 Breast Cancer Symposium entitled A New Targeted Strategy for Treating Bone Metastases in Breast Cancer Patients: Inhibiting RANK Ligand
Date of release: October 13, 2008
Date expires: October 13, 2009
Duration: 28:14
Click Here For More Information
Evaluating the strategy of inhibiting RANK Ligand in the treatment of breast cancer: a review of clinical data
Allan Lipton, MD
Session 7 from the ancillary event held at the 2008 Breast Cancer Symposium entitled A New Targeted Strategy for Treating Bone Metastases in Breast Cancer Patients: Inhibiting RANK Ligand
Date of release: October 13, 2008
Date expires: October 13, 2009
Duration: 07:24
Click Here For More Information
The potential role for RANK Ligand inhibition in the management of bone integrity in patients with metastatic breast cancer
Catherine Van Poznak, MD
Session 8 from the ancillary event held at the 2008 Breast Cancer Symposium entitled A New Targeted Strategy for Treating Bone Metastases in Breast Cancer Patients: Inhibiting RANK Ligand
Date of release: October 13, 2008
Date expires: October 13, 2009
Duration: 14:09
Click Here For More Information
Predicting who will develop breast cancer
Malcom C. Pike, PhD
Session 1a from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 17:20
Click Here For More Information
The clinical application of genetic testing for breast cancer prevention
Jeffrey N. Weitzel, MD
Session 1b from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 20:01
Click Here For More Information
Drug prevention strategies using SERMS and other agents for patients at high risk of developing breast cancer
Powel H. Brown, MD, PhD
Session 1c from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 19:22
Click Here For More Information
Point-Counterpoint: All patients at high risk for developing breast cancer should receive SERMS prophylactically
Powel H. Brown, MD, PhD vs. Jeffrey N. Weitzel, MD
Session 1d from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 19:55
Click Here For More Information
Session 1 Case Study
Mark Pegram, MD
Session 1e from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 9:03
Click Here For More Information
Panel Discussion, Q & A, and Consensus on the Status of the Data Presented in this Session
Mark Pegram, MD, Powel H. Brown, MD, PhD, Malcom C. Pike, PhD, and Jeffrey N. Weitzel, MD
Session 1f from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 9:53
Click Here For More Information
In which patients with breast cancer are gene expression arrays beneficial as prognostic markers today?
Charles M. Perou, PhD
Session 2a from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 18:24
Click Here For More Information
Response to Neoadjuvant Chemotherapy: what we can predict to do and what we cannot
Lajos Pusztai, MD, DPhil
Session 2b from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 22:43
Click Here For More Information
Point-Counterpoint: Use the 70-gene microarray assay versus the 21-gene panel assay for testing ER+, node-negative breast cancer
Lajos Pusztai, MD, DPhil vs. George W. Sledge, Jr., MD
Session 2c from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 22:29
Click Here For More Information
Session 2 Case Study
Harold J. Burstein, MD, PhD
Session 2d from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 1:57
Click Here For More Information
Panel Discussion, Q & A, and Consensus on the Status of the Data Presented in this Session
Harold J. Burstein, MD, PhD, Charles M. Perou, PhD, Lajos Pusztai, MD, DPhil, and George W. Sledge, Jr., MD
Session 2e from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 16:50
Click Here For More Information
Individualizing local-regional control with neo-adjuvant chemotherapy
Eleftherios P. Mamounas, MD, MPH, FACS
Session 3a from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 33:40
Click Here For More Information
Personalizing radiation therapy for breast cancer
Lori J. Pierce, MD
Session 3b from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 27:23
Click Here For More Information
Personalizing surgical therapy for breast cancer
Kelly K. Hunt, MD, FACS
Session 3c from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 29:00
Click Here For More Information
Point-Counterpoint: T[a taxane]+ C[a platinum]+ H[an anti-HER2] should replace anthracycline-based therapies for adjuvant therapy of HER2-positive breast cancer
Dennis J. Slamon, MD, PhD vs. Harold J. Burstein, MD, PhD
Session 3d from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 28:47
Click Here For More Information
Panel Discussion, Q & A, and Consensus on the Status of the Data Presented in this Session
Lori J. Pierce, MD, Harold J. Burstein, MD, PhD, Kelly K. Hunt, MD, FACS, Eleftherios P. Mamounas, MD, MPH, FACS, and Dennis J. Slamon, MD, PhD
Session 3e from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 16:50
Click Here For More Information
Personalized approaches to selecting targeted therapies and chemotherapies for metastatic HER2+ breast cancer patients
Dennis J. Slamon, MD, PhD
Session 4a from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 24:05
Click Here For More Information
Predictors of response and personalized approaches for selecting patients with HER2+ breast cancer for adjuvant and neo-adjuvant anti-HER2 therapy
Carlos L. Arteaga, MD
Session 4b from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 21:48
Click Here For More Information
The relationship between HER2 expression and response to taxane-based therapies
Hyman Muss, MD
Session 4c from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 13:30
Click Here For More Information
Point-Counterpoint: Adjuvant anti-HER2 therapy should be considered for HER2-negative patients?
Hyman Muss, MD vs. Michael F. Press, MD, PhD
Session 4d from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 30:05
Click Here For More Information
Point-Counterpoint: A taxane plus an alkylating agent should replace anthracycline-based therapies for adjuvant therapy of HER2-negative breast cancer
Hyman Muss, MD vs. Harold J. Burstein, MD, PhD
Session 4e from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 30:23
Click Here For More Information
Panel Discussion, Q & A, and Consensus on the Status of the Data Presented in this Session
Dennis J. Slamon, MD, PhD, Carlos L. Arteaga, MD, Harold J. Burstein, MD, PhD, Hyman Muss, MD, and Michael F. Press, MD, PhD
Session 4f from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 11:39
Click Here For More Information
What are the molecular predictors of response to adjuvant endocrine therapy?
W. Fraser Symmans, MD
Session 5a from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 20:46
Click Here For More Information
Are there personalized strategies for overcoming resistance to endocrine therapy?
V. Craig Jordan, OBE, PhD, DSc
Session 5b from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 18:54
Click Here For More Information
Personalized approaches to treating patients with ER+ breast cancer using single nucleotide polymorphisms (SNPs)
David Flockhart, MD, PhD
Session 5c from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 17:24
Click Here For More Information
Point-Counterpoint: Systemic therapy for the elderly should be identical to that for younger patients
Edith A. Perez, MD vs. George W. Sledge, Jr., MD
Session 5d from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 24:26
Click Here For More Information
Session 5 Case Study
Edith A. Perez, MD
Session 5e from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 9:08
Click Here For More Information
Panel Discussion, Q & A, and Consensus on the Status of the Data Presented in this Session
Edith A. Perez, MD, David Flockhart, MD, PhD, V. Craig Jordan, OBE, PhD, DSc, George W. Sledge, Jr., MD, and W. Fraser Symmans, MD
Session 5f from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 26:37
Click Here For More Information
Pathology and molecular classification of Triple-Negative Carcinoma
Edi Brogi, MD, PhD
Session 6a from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 28:49
Click Here For More Information
Personalizing breast cancer therapies using anti-angiogenic strategies
George W. Sledge, Jr., MD
Session 6b from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 20:30
Click Here For More Information
Therapeutic individualization with specific chemotherapeutic agents
Lisa A. Carey, MD
Session 6c from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 18:28
Click Here For More Information
Point-Counterpoint: All triple-negative patients should receive platinum-based adjuvant therapy
Lisa A. Carey, MD vs. Clifford A. Hudis, MD
Session 6d from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 20:11
Click Here For More Information
Session 6 Case Studies
Lisa A. Carey, MD and Clifford A. Hudis, MD
Session 6e from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 20:37
Click Here For More Information
Panel Discussion, Q & A, and Consensus on the Status of the Data Presented in this Session
Lisa A. Carey, MD, Clifford A. Hudis, MD, Edi Brogi, MD, PhD, and George W. Sledge, Jr., MD
Session 6f from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 13:44
Click Here For More Information
Drugs treating bone metastases: are they supportive care agents, therapeutics, or both?
Katherine Weilbaecher, MD
Session 7a from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 28:39
Click Here For More Information
Newer clinical strategies for treating bone metastases
Allan Lipton, MD
Session 7b from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 18:19
Click Here For More Information
Point-Counterpoint: Drugs treating bone metastases should be offered to patients as an option for adjuvant therapy of breast cancer
Allan Lipton, MD vs. Katherine Weilbaecher, MD
Session 7c from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 25:42
Click Here For More Information
Session 7 Case Study
Allan Lipton, MD
Session 7d from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 2:04
Click Here For More Information
Panel Discussion, Q & A, and Consensus on the Status of the Data Presented in this Session
Allan Lipton, MD and Katherine Weilbaecher, MD
Session 7e from the live course held on January 24-25, 2009 in Miami, FL entitled Second Annual Symposium on Personalized Therapies for Breast Cancer
Date of release: March 9, 2009
Date expires: March 9, 2010
Duration: 11:14
Click Here For More Information
|
